Weight-Loss Agents

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly; Ascletis reports early obesity results

2 weeks ago talkbio0Tagged ASC41, Ascletis, eli lilly, Glucagon-Like Peptide 1, GSBR-1290, Obesity, Oral cavity, Ozempic, Phase 2 trial, safety profile, Structure Therapeutics, Wegovy, Weight Loss, Weight-Loss Agents, Zepbound

Structure Therapeutics; GSBR-1290; oral GLP-1; obesity pill; weight-loss drug; Novo Nordisk; Eli Lilly; Wegovy; Ozempic; Zepbound; Ascletis; ASC41; ASC42; phase 1 trial; phase 2 trial; weight reduction; safety profile

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

1 month ago talkbio0Tagged Capitalization, Drug Industry, eli lilly, Glucagon-Like Peptide 1, Market, Mounjaro, valuation, Weight-Loss Agents, Zepbound

Eli Lilly; trillion-dollar valuation; weight-loss drugs; Mounjaro; Zepbound; GLP-1 market; pharmaceutical industry; stock market; market capitalization

From Weight Loss to Hair Loss: The Search for the Next Blockbuster – Recent Developments and News (2024-2025)

1 month ago talkbio0Tagged Alopecia, Androgenetic Alopecia, baldness cure, blockbuster drugs, Glucagon-Like Peptide 1, Investments, minoxidil, pattern hair loss, Pelage Pharmaceuticals, PP405, Veradermics, Weight-Loss Agents

weight loss drugs; GLP-1; hair loss treatments; Pelage Pharmaceuticals; Veradermics; blockbuster drugs; pattern hair loss; baldness cure; minoxidil; PP405; androgenetic alopecia; biotech investment

Weight-loss Drugs Lead Latest Batch of FDA Priority Voucher Recipients

1 month ago talkbio0Tagged Commissioner 's National Priority Voucher, drug price, eli lilly, fast-track approval, Nordisk, priority review vouchers, United States Food and Drug Administration, Wegovy, Weight-Loss Agents

FDA; priority review vouchers; weight-loss drugs; Wegovy; orforglipron; Eli Lilly; Novo Nordisk; drug pricing; fast-track approval; Commissioner’s National Priority Voucher

Trump Announces Sweeping Cost Cuts on Lilly and Novo Weight Loss Drugs in Exchange for Medicare Coverage

1 month ago talkbio0Tagged drug price, Eli Lilly ; Novo Nordisk, Glucagon-Like Peptide 1, Medicaid, Medicare, Prices, Transplant Registry Unified Management Program, Wegovy, Weight-Loss Agents, Zepbound

Trump; Eli Lilly; Novo Nordisk; weight loss drugs; GLP-1; Medicare; Medicaid; Wegovy; Zepbound; price cuts; drug pricing deal

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

2 months ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

2 months ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Weight-loss drug stocks drop after Trump pledges major price cuts

2 months ago talkbio0Tagged Administration occupational activities, Drops - Drug Form, drug price, eli lilly, Glucagon-Like Peptide 1, Nordisk, Ozempic, Wegovy, Weight-Loss Agents

weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1

Skye Bioscience’s Nimacimab Fails Mid-Stage Obesity Trial, Stock Plummets

3 months ago talkbio0Tagged CB1 inhibitor, Clinical Setback, Nimacimab, Obesity Trial, Weight-Loss Agents

nimacimab; CB1 inhibitor; obesity trial; clinical setback; weight loss drug

Roche’s Top Three Ambition in Obesity Not Dependent on a Single Megablockbuster

3 months ago talkbio0Tagged cardiometabolic care, Diagnostics, digital health, Ecosystem, Obesity, Portfolio diversification, Roche (company), Weight-Loss Agents

Roche; obesity strategy; ecosystem approach; pharmaceuticals; diagnostics; digital health; cardiometabolic care; portfolio diversification; weight-loss drugs